ImmunityBio (NasdaqGS:IBRX) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsClara Dong - VP, Equity Research in BiotechnologyJason Kolbert - Managing Director, Head of Equity ResearchPatrick Soon-Shiong - Founder, Executive Chairman, and Global Chief Scientific and Medical OfficerRichard Adcock - President and CEOConference Call ParticipantsAndres Maldonado - Senior Biotechnology AnalystEdward Tenthoff - Biotech Equity Research AnalystJeet Mukherjee - VP and Biotechnology AnalystOperato ...

Crexendo (NasdaqCM:CXDO) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsDoug Gaylor - President and COOEric Martinuzzi - Founding Partner an COOGeorge Sutton - Partner and Co-Director of ResearchJeff Korn - CEO and Chairman of the BoardJon D. Brinton - Chief Revenue OfficerMatt Maus - Equity Research AssociateRon Vincent - CFOConference Call ParticipantsJoshua Reilly - Managing Director and Senior Research AnalystMike Latimore - Managing Director and Equity AnalystOperatorPlease note, ...

Crexendo (NasdaqCM:CXDO) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsDoug Gaylor - President and COOEric Martinuzzi - Founding Partner an COOGeorge Sutton - Partner and Co-Director of ResearchJeff Korn - CEO and Chairman of the BoardJon D. Brinton - Chief Revenue OfficerMatt Maus - Equity Research AssociateRon Vincent - CFOConference Call ParticipantsJoshua Reilly - Managing Director and Senior Research AnalystMike Latimore - Managing Director and Equity AnalystOperatorPlease note, ...

Rigel Pharmaceuticals (NasdaqGS:RIGL) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAshley Aloupis - Equity Research AssociateDavid Santos - Chief Commercial OfficerDean Schorno - CFOJoe Pantginis - Managing Director of Equity ResearchLisa Rojkjaer - EVP and Chief Medical OfficerRaul Rodriguez - President and CEORaymond Furey - EVP, General Counsel and Corporate SecretaryConference Call ParticipantsFarzin Haque - SVP and Biotechnology Equity Research AnalystKristen Kluska - Director a ...

Rigel Pharmaceuticals (NasdaqGS:RIGL) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAshleigh Acker - Biotechnology Equity Research AssociateDave Santos - Chief Commercial OfficerDean Schorno - CFOJoe Pantginis - Managing Director of Equity ResearchLisa Rojkjaer - EVP and Chief Medical OfficerRaul Rodriguez - President and CEORay Furey - EVP, General Counsel and Corporate SecretaryConference Call ParticipantsFarzin Haque - SVP and Biotechnology Equity Research AnalystKristen Kluska - D ...

Financial Performance - The company reported combined revenues of $13.7 million for Q4 2025, a 31% increase year-over-year, and total revenues of $44.5 million for the full year, up 18% from 2024 [6][22] - Adjusted earnings improved by over $2 million to $1.7 million or $0.11 per share, with cash flow from operations increasing by $5.5 million to just under $5 million for the year [6][25] - The net loss for Q4 was approximately $1.4 million, and for the full year, it was $2.9 million, both significantly improved compared to 2024 [24] Business Line Performance - Revenues by product for Q4 included $3.1 million for Kristalose, $3.3 million for Sancuso, $2.8 million for Vibativ, $0.9 million for Caldolor, and $3.3 million for Talicia [22] - For the full year, product revenues totaled $10.5 million for Kristalose, $11.9 million for Sancuso, $9.4 million for Vibativ, $4.7 million for Caldolor, and $3.3 million for Talicia [23] Market Expansion - Vibativ received regulatory approval in China and was launched in Saudi Arabia, creating significant new opportunities [7] - The company also received regulatory approval for its ibuprofen injection product in Mexico, further expanding its international market presence [7] Strategic Developments - The company acquired Talicia, an FDA-approved treatment for Helicobacter pylori infections, enhancing its gastrointestinal care portfolio [8] - A J-code for Caldolor was issued by CMS, improving product access and supporting its growth as a standard of care for pain and fever [8] Management Commentary - Management expressed optimism about the company's future, highlighting strong financial performance, global expansion, and advancements in the clinical pipeline [5][29] - The company is targeting double-digit revenue growth for 2026, driven by in-line brands and the new addition of Talicia [30] Other Important Information - The company strengthened its balance sheet by increasing shareholder equity and reducing its line of credit balance by over $10 million [6][7] - Cumberland holds over $54 million in tax net operating loss carryforwards, primarily from prior stock option exercises [28] Q&A Session Summary - There were no questions from participants during the call, and management expressed willingness to engage in private discussions with shareholders if desired [32][33]

SoundThinking (NasdaqCM:SSTI) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAlan Stewart - CFOAlex Latimore - Research AssociateElle Niebuhr - Equity Research AssociateRalph Clark - CEOConference Call ParticipantsJeremy Hamblin - Senior Research AnalystTrevor Walsh - Director and Senior Equity Research AnalystOperatorGood afternoon, and welcome to SoundThinking's fourth quarter and full year 2025 earnings conference call. My name is Diego, and I will be your operator for today's call. ...

Latham Group (NasdaqGS:SWIM) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsAnika Dholakia - Equity Research AssociateCasey Kotary - Investor Relations RepresentativeOliver Gloe - CFOSean Callan - Equity Research AssociateSean Gadd - President and CEOConference Call ParticipantsDaniel Eggerichs - AnalystGreg Palm - Senior Research AnalystScott Schrier - VP and Equity Research AnalystSusan Maklari - Senior Equity Research AnalystTim Weiss - Senior Research AnalystOperatorWelcome to the ...

ImmunityBio (NasdaqGS:IBRX) Q4 2025 Earnings call March 03, 2026 04:30 PM ET Company ParticipantsClara Dong - VP, Equity Research in BiotechnologyJason Kolbert - Managing Director, Head of Equity ResearchPatrick Soon-Shiong - Founder, Executive Chairman, and Global Chief Scientific and Medical OfficerRichard Adcock - President and CEOConference Call ParticipantsAndres Maldonado - Senior Biotechnology AnalystJeet Mukherjee - VP and Biotechnology AnalystTed Tenthoff - Biotech Equity Research AnalystOperatorGo ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $330.7 million, down 4.1% on a constant currency basis and 6.3% on a reported basis, primarily due to declines in advertising and IP adaptations [10][11] - Full year 2025 revenue was $1.4 billion, growing 3.9% on a constant currency basis and 2.5% on a reported basis [10] - Adjusted EBITDA for Q4 was $0.6 million, exceeding guidance, compared to a negative adjusted EBITDA of $3.5 million in Q4 2024 [12] - The net loss for Q4 was $336.5 million, compared to a loss of $102.6 million in the prior year, driven by goodwill impairments [11][25] - Full year adjusted EBITDA was $19.4 million, down from $68 million in the prior year [12][23] Business Line Data and Key Metrics Changes - Paid content revenue grew 0.4% on a constant currency basis in Q4, while full year growth was 1.5% [14][15] - Advertising revenue declined 10.3% in Q4 on a constant currency basis, but grew 0.4% for the full year [16] - IP adaptation revenue saw a significant decline of 29.7% in Q4 on a constant currency basis, but grew 35.5% for the full year [16][17] Market Data and Key Metrics Changes - In Korea, Q4 revenue declined 9.1% on a constant currency basis, while full year revenue grew 5.9% [17] - Japan's Q4 revenue declined 1.0% on a constant currency basis, with full year growth of 3.9% [19] - The rest of the world saw Q4 revenue growth of 0.8% on a constant currency basis, but a full year decline of 2.1% [21] Company Strategy and Development Direction - The company is focusing on enhancing its personalization tools and AI-driven content recommendations to improve user engagement [5][6] - A strategic agreement with Disney was completed, targeting a 2026 launch for a new digital comics platform [6][7] - The company aims to deepen engagement across its platform and accelerate its growth potential [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to double-digit year-over-year growth by the end of 2026, driven by improvements in paid content and advertising [27][36] - The company acknowledged challenges in the advertising sector but remains optimistic about its long-term strategy and market position [27][36] Other Important Information - The company reported a cash balance of $582 million at year-end, indicating strong financial health [26] - The company is investing in infrastructure and product development to support future growth [20][61] Q&A Session Summary Question: Details on the Disney platform launch - Management confirmed that Disney's investment was completed, and 12 reformatted titles have been launched, with a commitment to original stories in 2026 [31][33] Question: Factors for double-digit growth - Management highlighted that growth will come from paid content recovery, advertising improvements, and crossover IP opportunities [36][62] Question: Key learnings from recommendation algorithms in Korea - The company noted strong performance metrics in Korea and plans to apply successful strategies to other markets [41][42] Question: Competitive dynamics for attracting creators - Management emphasized the importance of a healthy base of paying users to attract and retain creators, with ongoing investments in content development [43][44] Question: Economics of the new Disney platform - Management stated that WEBTOON will recognize all revenue and costs for the new platform, with a structure consistent with existing business models [52] Question: Advertising ecosystem shifts - Management acknowledged the need to build a tailored advertising infrastructure for the North American market while maintaining a focus on long-term growth [72]